These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2569306)

  • 1. Detection of renal impairment in cases of chronic abuse of analgesics by administration of desamino-D-arginine vasopressin.
    Wambach G; Bönner G; Kleinpass H; Dopatka A; Kaufmann W
    Arzneimittelforschung; 1989 Mar; 39(3):387-90. PubMed ID: 2569306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine osmolality, cyclic AMP and aquaporin-2 in urine of patients under lithium treatment in response to water loading followed by vasopressin administration.
    Wilting I; Baumgarten R; Movig KL; van Laarhoven J; Apperloo AJ; Nolen WA; Heerdink ER; Knoers NV; Egberts AC
    Eur J Pharmacol; 2007 Jul; 566(1-3):50-7. PubMed ID: 17466972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of a single dose of vasopressin analogs on human renal potassium excretion.
    Nádvorníková H; Schück O
    Int J Clin Pharmacol Ther Toxicol; 1982 Apr; 20(4):155-8. PubMed ID: 7076344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-desamino-8-D-arginine vasopressin (DDAVP) concentration test.
    Radó JP
    Am J Med Sci; 1978; 275(1):43-52. PubMed ID: 665711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desamino arginine vasopressin (DDAVP) as a diagnostic agent.
    Somerfield SD; Hocken AG
    N Z Med J; 1977 Nov; 86(600):472-3. PubMed ID: 343010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiuretic action of oxytocin is associated with increased urinary excretion of aquaporin-2.
    Joo KW; Jeon US; Kim GH; Park J; Oh YK; Kim YS; Ahn C; Kim S; Kim SY; Lee JS; Han JS
    Nephrol Dial Transplant; 2004 Oct; 19(10):2480-6. PubMed ID: 15280526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical aspects and renal function in patients with endemic nephropathy].
    Bukvić D; Djukanović L; Janković S
    Srp Arh Celok Lek; 2003; 131(1-2):10-6. PubMed ID: 14608855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephropathy as a hazard of analgesic abuse.
    Anandan JV; Matzke GR
    Am J Hosp Pharm; 1981 Oct; 38(10):1536-9. PubMed ID: 7294057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A standardized desmopressin test of renal concentrating ability.
    Nadvorníková H; Schück O; Cort JH
    Clin Nephrol; 1980 Sep; 14(3):142-7. PubMed ID: 7418281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analgesic nephropathy: an important cause of chronic renal failure.
    Cove-Smith JR; Knapp MS
    Q J Med; 1978 Jan; 47(185):49-69. PubMed ID: 674550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The urinary excretion of selenium in sheep treated with a vasopressin analogue.
    Leng L; Boldizárová K; Faix S; Kovác G
    Vet Res; 2000; 31(5):499-505. PubMed ID: 11050745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experiences with the intranasal and parenteral use of 1-desamino-8-D-arginine vasopressin (DDAVP)--effect of one time parenteral and intranasal applications].
    Tuschy U; Meinhold J; Szeszat S
    Z Gesamte Inn Med; 1983 Aug; 38(16):450-2. PubMed ID: 6636913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regulation of natriuresis in diabetic nephropathy].
    Późniak J
    Ann Acad Med Stetin; 2000; 46():241-52. PubMed ID: 11712308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of analgesic nephropathy in women on the metabolism and excretion of 14C-acetaminophen.
    Thomas BH; Hynie I; Zeitz W
    Int J Clin Pharmacol Ther Toxicol; 1980 Jan; 18(1):26-30. PubMed ID: 7364530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern of renal dysfunction in analgesic nephropathy--comparison with glomerulonephritis.
    Nanra RS
    Nephrol Dial Transplant; 1992; 7(5):384-90. PubMed ID: 1321372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Analgesic Nephropathy Network of Europe.
    Elseviers MM; Waller I; Nenoy D; Levora J; Matousovic K; Tanquerel T; Pommer W; Schwarz A; Keller E; Thieler H
    Nephrol Dial Transplant; 1995; 10(6):808-14. PubMed ID: 7566608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The renal prostaglandin system in central diabetes insipidus: effects of desamino-arginine vasopressin.
    Düsing R; Herrmann R; Kramer HJ
    Adv Prostaglandin Thromboxane Res; 1980; 7():1111-3. PubMed ID: 6245565
    [No Abstract]   [Full Text] [Related]  

  • 18. Possible involvement of urokinase-type plasminogen activator release from human peripheral blood lymphocytes in the pathophysiology of chronic allograft nephropathy.
    Yamaguchi Y; Suzuki T; Arita S; Iwashita C; Sakamoto K; Hatakeyama E; Shimmura H; Tanabe K; Ichinose M; Suzuki N; Yamada K
    Transplant Proc; 2005 Dec; 37(10):4276-81. PubMed ID: 16387096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal prostaglandins and water balance: studies in normal volunteer subjects and in patients with central diabetes insipidus.
    Düsing R; Herrmann R; Glänzer K; Vetter H; Overlack A; Kramer HJ
    Clin Sci (Lond); 1981 Jul; 61(1):61-7. PubMed ID: 6265142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of DDAVP on renal hemodynamics and renin secretion in subjects with essential hypertension.
    Brink HS; Derkx FH; Boomsma F; Schalekamp MA
    Clin Nephrol; 1994 Aug; 42(2):95-101. PubMed ID: 7955585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.